GPX4 controls ferroptosis, and new drugs aim to switch it on or off

Ferroptosis is a regulated form of cell death caused by iron-dependent lipid peroxidation of cell membranes. It is increasingly linked to age-related and degenerative disease, which makes the pathways controlling it relevant to longevity science. Glutathione peroxidase 4 (GPX4), a selenium-containing enzyme, is central to this process because it neutralizes damaging phospholipid hydroperoxides.

This Trends in Molecular Medicine article is a narrative review, not a new experiment. It surveys how GPX4 is regulated at multiple layers. At the gene level, transcription factors, epigenetic modifications, and noncoding RNAs affect GPX4 transcription and mRNA stability. At the protein level, post-translational modifications determine GPX4 degradation and activity. The abstract lists ubiquitination, phosphorylation, palmitoylation, methylation, hydroxylation, and lactylation.

The review connects GPX4 to several conditions, including cancer, neurodegeneration, acute renal failure, and infection. In general terms, too little GPX4 activity can promote tissue damage through excess ferroptosis, whereas high GPX4 activity may help some tumors resist cell death. The review also summarizes new therapeutic strategies in two directions: ferroptosis inducers intended for cancer therapy, and ferroptosis inhibitors intended to limit ferroptosis-related damage.

The implication is that GPX4 regulation offers many possible drug targets, since each control point could be modulated. This could support more selective treatments than directly blocking the enzyme.

Caveats: only the abstract was available, so specific compounds, quantitative data, and clinical-stage evidence cannot be assessed. As a review, it reflects the author's selection of the literature, and much of the underlying work is likely preclinical. Targeting GPX4 also risks affecting healthy tissues, and nothing here supports using it in personal health decisions.